FluoGuide releases positive interim result of FG001 in head and neck cancer

Copenhagen, Denmark, 9 January 2023 – FluoGuide A/S ("FluoGuide" or the "Company") is pleased to announce the positive interim result of FG001 in head and neck cancer that FG001 lights up in 4 out of 4 patients following the interim evaluation of the first four patients dosed in the ongoing explorative phase IIa trial in patients with head and neck squamous cell carcinomas (HNSCC) undergoing surgery.

The release as fetched from its publisher. fluoguide.com ↗